Answers are grounded in this paper and cite their sources.
Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with Staphylococcus aureus bacteremia. In this study, the activity of ceftobiprole and comparators was evaluated against more than 7,300 clinical isolates collected in the United States from 2016 through 2018 from patients with skin and skin structure infections.
No takes yet. Share an insight, caveat, or question.
Flamm et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: